Navigation Links
KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH
Date:11/7/2013

KB001-A, KB003 and KB004. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the company's limited cash reserves and its ability to obtain additional capital on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that the company has initiated or plans to initiate; the company's dependence on Sanofi Pasteur for the development and commercialization of KB001-A; the company's ability to successfully complete further development of its programs; the uncertainties inherent in clinical testing, including time to enroll clinical studies; the timing, cost and uncertainty of obtaining regulatory approvals; the company's ability to protect the company's intellectual property; competition; changes in the regulatory landscape or the imposition of regulations that affect the company's products; and other factors listed under "Risk Factors" in the company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 1, 2013, the quarterly reports on Form 10-Q filed on May 14, 2013 and August 19, 2013, and the company's other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The company has no obligation, and expressly disclaims any obligation to update, revise
'/>"/>

SOURCE KaloBios Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology news :

1. Cell therapy using patients own bone marrow may present option for heart disease
2. Report presents designs for study of cancer risks near US nuclear facilities
3. Entomology 2012 to present 105 insect symposia in November
4. NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards
5. The Brain Prize 2012 is presented May 9th
6. Validity CTO to Present Natural ID Solutions for Improving Mobile Risk Management and User Experience at NFC Solutions Summit 2012
7. John Theurer Cancer Center presents significant blood cancer research at 2012 ASCO Annual Meeting
8. Amarantus BioSciences to Present at the National Investment Banking Associations (NIBA)122nd Conference in New York City
9. Coral reef experts to present latest coral reef science during July symposium
10. FirstMark Exhibiting and Presenting at the San Diego Academy of Family Physicians 55th Annual Postgraduate Symposium
11. GSA Bulletin presents studies in Antarctica, Italy, Mexico, Algeria, Mongolia, and more
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... A recent report, "Genetic Testing Market Outlook 2018", provides ... testing market. A comprehensive introduction of gene-based tests, their ... On account of our analysis of the past and ... forecast for genetic testing has been drawn, according to ... CAGR of around 9% during 2013-2018. Our report ...
(Date:10/22/2014)... (NASDAQ: AWRE ), a leading supplier of biometrics ... quarter ended September 30, 2014. Revenue for the ... 40% compared to $4.3 million in the same quarter last ... $4.1 million compared to $1.0 million in the third quarter ... period was primarily due to: i) a $1.0 million increase ...
(Date:10/17/2014)... is critical and pertinent for practicing physicians and clinicians ... epidemic. The Journal, Disaster Medicine and Public Health ... and Public Health, to surround the public, medical professionals ... moment. , On October 17, the journal published ... primer was prepared by Dr. Eric Toner, internist and ...
Breaking Biology News(10 mins):Genetic Testing Market Outlook 2018 2Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7
... Groundbreaking research led by the U.S. Department of Energy ... time that the signatures of the genes alone in ... of the sampled environments. This study, published in the ... genome sequencing to accelerate advances in environmental sciences akin ...
... throughput microarray analyses result in many differentially expressed ... process of interest. In order to identify biological ... in which pairs of gene names and combinations ... , MEDLINE search strings for 15,621 known genes ...
... Joslin Diabetes Center have found genetic regions that, when defective, ... in a series of mis-steps that lead to type 1 ... journal Immunity, the researchers are now trying to hone in ... patients. , “The significance of this study is that we ...
Cached Biology News:Study reveals new technique for fingerprinting environmental samples 2Study reveals new technique for fingerprinting environmental samples 3Genetic defects give the immune system the green light to attack the pancreas 2Genetic defects give the immune system the green light to attack the pancreas 3
(Date:10/22/2014)... SC (PRWEB) October 22, 2014 ... of its cardiovascular pharmacogenetics menu, which enables healthcare ... outcomes. With PCLS’s evidence-based results, healthcare providers ... and optimize their therapy, while minimizing risks for ... the U.S., according to the FDA [1] more ...
(Date:10/22/2014)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... its Oral Amphotericin B program.  The company recently ... work involving samples from HIV/AIDS patients exposed ... pre clinical studies and regulatory filings to move ... utilizing approximately $700,000 of funding and technological advice ...
(Date:10/22/2014)... DIEGO and HONG KONG ... innovative rare disease therapeutics enterprise, announced today that rare ... the company as vice president, research. Dr. McKew brings ... including key leadership positions at the National Institutes of ... its acquisition by Wyeth). Dr. McKew will lead aTyr,s efforts ...
(Date:10/20/2014)... October 20, 2014 Convey Computer ... a team from Iowa State University won first place ... Using a Convey HC-2ex, the team’s solution achieved the ... faster than the second place finisher. , Experts from ... upon the month long challenge, using a variety of ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3
... Conn. , April 28 Goodwin Biotechnology Inc., a full ... development services company, jointly announced today their collaborative agreement to create ... services. , , , ... collaboration will enhance and strengthen the clinical development services integrating cDNA ...
... 28 The global biotechnology industry was able to ... financial performance in 2009, with the world,s established biotech centers ... gap between the "haves" and "have nots" in the industry ... companies in accessing the capital needed for R&D. These and ...
... ... of its Global Food, Agribusiness and Biofuels practice, presents findings today from a new ... and Agricultural Infrastructure" at the Land Conference 2010 organized by The World Bank in ... ...
Cached Biology Technology:Goodwin Biotechnology Inc. and Hyprocell LLC Announce Collaboration 2Goodwin Biotechnology Inc. and Hyprocell LLC Announce Collaboration 3Biotech Industry Showing Resilience Despite Challenging Conditions 2Biotech Industry Showing Resilience Despite Challenging Conditions 3Biotech Industry Showing Resilience Despite Challenging Conditions 4Biotech Industry Showing Resilience Despite Challenging Conditions 5Biotech Industry Showing Resilience Despite Challenging Conditions 6Biotech Industry Showing Resilience Despite Challenging Conditions 7Private Sector Investment in Agriculture Emerging as a Significant Alternative Asset Class: New HighQuest Partners Study 2Private Sector Investment in Agriculture Emerging as a Significant Alternative Asset Class: New HighQuest Partners Study 3Private Sector Investment in Agriculture Emerging as a Significant Alternative Asset Class: New HighQuest Partners Study 4
Determine relative degree of protein binding to phosphoinositides...
PA coated Agarose beads LPA Beads...
Mouse monoclonal antibody to RNase L...
Volume adapter mounts on top of the 96 well FiltrEX filter plate and allows larger volumes (1mL) to be applied to each well in a filter plate. Adapters are nonsterile....
Biology Products: